Rise of AI continues to re-write life sciences IP strategies in 2022
A spate of pharma-high tech innovation partnerships have dominated opening days of the year
A spate of pharma-high tech innovation partnerships have dominated opening days of the year
“We are literally down to the last few important items now,” says company CEO John Chen on Q3 earnings call
The company is due to release its Q3 financials tomorrow, but it is not known whether the touted sale of a portfolio of well over 30,000 individual assets will also be announced
Diagnostic innovation buyouts drive resurgence of med-tech deal-making
19 October 2021
Continued impact of Samsung deal pushes Swedish company’s royalty take near $300 million – but executives warn upcoming re-negotiations could produce temporary disruption again
19 October 2021
Merck has struck the biggest life sciences M&A deal of 2021 so far. Here are the four key IP-related takeaways.
07 October 2021
US federal court victory sets up the $13.4 billion drug for exclusivity until 2028
05 October 2021
Assignment records show that despite parent company’s vast backing for startups, Softbank Corp and its affiliates have not often come into the possession of significant third-party portfolios
04 October 2021
The Long Read: Companies in the life sciences sector have increasing options when seeking outside investment in IP enforcement campaigns, writes Michael Gulliford. But unique legal considerations and risk factors call for careful structuring of deals
29 September 2021
World-beating R&D and patent rates propel country to top of Asia for the first time in annual WIPO study, but Global Innovation Index also shows areas where IP professionals can help it improve further
27 September 2021
Saturday Opinion: Recent signs point toward more patent licensing negotiations between Chinese tech companies. That’s good news for the country’s IP system.
25 September 2021
A new high-level policy calls for growth by a metric that includes not just royalty receipts but also payments to foreign IP owners
23 September 2021
Financial disclosures from four major publicly-listed patent owners suggest that their collective licensing revenues are on a downward trend
06 September 2021
Get unlimited access to all IAM content